Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 10/20 | 0.70 |
| ▸ | MAOA | P21397 | 1/20 | 0.57 |
| ▸ | PADI6 | Q6TGC4 | 1/20 | 0.55 |
| ▸ | CTSL | P07711 | 4/20 | 0.53 |
| ▸ | CTSB | P07858 | 4/20 | 0.53 |
| ▸ | CTSS | P25774 | 4/20 | 0.53 |
| ▸ | CTSK | P43235 | 4/20 | 0.53 |
| ▸ | CTSV | O60911 | 3/20 | 0.53 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.52 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.50 |
| ▸ | PADI4 | Q9UM07 | 2/20 | 0.49 |
| ▸ | NPY1R | P25929 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17537334 | 1.00 | KDM1A (0.70) | KDM1AMAOAPADI6CTSLCTSB | |
| SCHEMBL15764509 | 0.91 | KDM1A (0.69) | KDM1AMAOAPADI6CTSLCTSB | |
| Hydrochloric Acid SCHEMBL17133710 | 0.90 | KDM1A (0.68) | KDM1AMAOAPADI6CTSLCTSB | |
| SCHEMBL17133640 | 0.89 | KDM1A (0.68) | KDM1AMAOAPADI6KDM1BPADI4 | |
| SCHEMBL15764513 | 0.89 | KDM1A (0.68) | KDM1AMAOAPADI6KDM1BPADI4 | |
| SCHEMBL15764514 | 0.88 | KDM1A (0.56) | KDM1AMAOAPADI6CTSBCTSS | |
| SCHEMBL15764510 | 0.85 | KDM1A (0.62) | KDM1AMAOAPADI6CTSLCTSB | |
| SCHEMBL17133721 | 0.84 | KDM1A (0.64) | KDM1AMAOAPADI6CTSLCTSB | |
| SCHEMBL17537310 | 0.84 | KDM1A (0.64) | KDM1AMAOAPADI6CTSLCTSB | |
| SCHEMBL16155821 | 0.83 | KDM1A (0.63) | KDM1AMAOAPADI6CTSLCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9388123-B2 | LSD1-selective inhibitor having lysine structure | KYOTO UNIVERSITY (JP) | 2016-07-12 | — | — | US | disclosed |
| US-20160039748-A1 | LSD1-SELECTIVE INHIBITOR HAVING LYSINE STRUCTURE | KYOTO UNIVERSITY (JP) | 2016-02-11 | — | — | US | disclosed |
| EP-2927212-A1 | LSD1-SELECTIVE INHIBITOR HAVING LYSINE STRUCTURE | Kyoto University (JP) | 2015-10-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160039748-A1 | LSD1-SELECTIVE INHIBITOR HAVING LYSINE STRUCTURE | KDM1A, DOT1L, KDM1B | KDM1A 1/4885MAOA 247/4885PADI6 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.